Perry Calias, PhDChief Operating Officer at Revolo Biotherapeutics
Dr. Calias brings over 30 years of biopharmaceutical experience in clinical development across the drug and device sectors of healthcare. His strengths include pre-clinical, clinical development and global regulatory submissions. Dr. Calias has extensive experience in CNS and neurology as well as rare diseases. He has a strong track record in compound development and pipeline progression, as well as building research and development organizations. He is currently the Chief Operating Officer for Revolo Biotherapeutics, responsible for all products development, CMC, Regulatory, Toxicology and Quality. His previous experience includes serving as Chief Scientific Officer at Cerecor and Vice President of Global CMC and Product Development at Sucampo. He has held a variety of research and development positions both in clinical and non-clinical roles of expanded leadership at Pharming, Shire HGT Eyetech, Draper Labs and Genzyme.
Dr. Calias' strong background in early-stage asset development, as well as his clinical trial experience, as the ZEA Bioscience organization enters Phase 1 trials for our Hemophilia programs.
Dr. Calias obtained his Ph.D. in Bio-Organic Chemistry from Tufts University and his B.S. in biology from Suffolk University.